C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu-Reference-Cited by-同舟云学术

C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu

Published:2004 Issue:4 Volume:113 Page:678-682
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Lengyel Ernst,Prechtel Dieter,Resau James H.,Gauger Katja,Welk Anita,Lindemann Kristina,Salanti Georgia,Richter Thomas,Knudsen Beatrice,Vande Woude George F.,Harbeck Nadia

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference21 articles.

1. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

3. Met, metastasis, motility and more

4. Expression of c-met is a strong independent prognostic factor in breast carcinoma

Cited by 224 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epinephrine, Pregabalin, and Crizotinib as Three Medicines with Polish Implications over Three Last Centuries and in View of Three Different Drug Discovery Approaches;Biomedicines;2024-09-04

2. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy;Phytomedicine;2024-06

3. Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies;Drug Delivery and Translational Research;2024-04-10

4. MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling;British Journal of Cancer;2023-12-18

5. Breast cancer vaccination: Latest advances with an analytical focus on clinical trials;International Immunopharmacology;2023-10